Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
EJNMMI Research|January 24, 2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementationSteffie M B Peters, Maaike C T Mink, Bastiaan M Privé, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2021
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcomeSteffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 18, 2016
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsTheodosia Maina, Mark W Konijnenberg, Petra KolencPeitl, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapyBarry W Wessels, Mark W Konijnenberg, Roger G Dale, et al.EJNMMI Physics|December 28, 2019
Towards standardization of absolute SPECT/CT quantification: a multi-center and multi-vendor phantom studySteffie M B Peters, Niels R van der Werf, Marcel Segbers, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2015
Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and courseHendrik Bergsma, Mark W Konijnenberg, Boen L R Kam, et al.European Journal of Nuclear Medicine and Molecular Imaging|December 21, 2021
89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in manBastiaan M Privé, Yvonne H W Derks, Florian Rosar, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 24, 2019
Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE TherapyEdward O'Neill, Veerle Kersemans, P Danny Allen, et al.EJNMMI Physics|February 13, 2020
Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systemsSteffie M B Peters, Sebastiaan L Meyer Viol, Niels R van der Werf, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 23, 2020
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapyEline A M Ruigrok, Nicole van Vliet, Simone U Dalm, et al.Pageof 7